Share

November 2017; 4 (6) ArticleOpen Access

Teriflunomide treatment reduces B cells in patients with MS

Ilaria Gandoglia, Federico Ivaldi, Alice Laroni, Federica Benvenuto, Claudio Solaro, Gianluigi Mancardi, Nicole Kerlero de Rosbo, Antonio Uccelli
First published October 23, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000403
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
659

Share

Article Information

vol. 4 no. 6 e403
DOI: 
https://doi.org/10.1212/NXI.0000000000000403
PubMed: 
29082295
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 26, 2017
  • Accepted in final form August 10, 2017
  • First Published October 23, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Ilaria Gandoglia, MD,
    2. Federico Ivaldi,
    3. Alice Laroni, MD, PhD,
    4. Federica Benvenuto, PhD,
    5. Claudio Solaro, MD,
    6. Gianluigi Mancardi, MD,
    7. Nicole Kerlero de Rosbo, PhD* and
    8. Antonio Uccelli, MD*
  1. Ilaria Gandoglia, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I. Gandoglia has received funding for travel from Biogen, Novartis, and GenzymeI and from Almirall

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Federico Ivaldi,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Alice Laroni, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Sanofi (2) Merck

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) travel, Teva (2) speaker honoraria, Biogen (3)speaker honoraria, Teva (4) speaker honoraria, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Biogen, funding to a workshop organized by me

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Federica Benvenuto, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Claudio Solaro, MD,
    6. Scientific Advisory Boards:

    1. Merck-Seronno, Almirall, GWpharma, Biogen, TEVA, Novartis, Genzyme

    Gifts:

    1. Merck-Seronno, Almirall, GWpharma, Biogen, TEVA, Novartis, Genzyme

    Funding for travel or speaker honoraria:

    1. Merck-Seronno, Almirall, GWpharma, Biogen, TEVA, Novartis, Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Italian Multiple Sclerosis Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Gianluigi Mancardi, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi- Aventis and Teva Pharmaceuticals

    Editorial Boards:

    1. Associate Editor of Neurological Sciences

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Honoraria for speaking activities from Companies (Biogen Idec, Bayer Schering)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Italian Multiple Sclerosis Society (AISM) Grants 2001-R- 38 and 2002-R-36

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Nicole Kerlero de Rosbo, PhD* and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Antonio Uccelli, MD*
    9. Scientific Advisory Boards:

    1. Served on the Scientific Advisory Boards for Genetech (2009), Roche 2009- present), Allergan 2009-present

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Received funding for a trip to give a lecture from Athersys (2009)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Received honoraria to give lectures from Biogen Dompe', Serono Symposia, Sanofi Aventis, Tohoku University Graduate School of Medicine.

    Consultancies:

    1. Received consulting fee from Merck-Serono (2009), Biogen Domp? (2010)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received grant support from Bayer Schering (2009) and Sanofi Aventis (2009)

    Research Support, Government Entities:

    1. Funded as Principal Investigator from Italian Ministry of Health (RF-LIG- 2007-647513) (2008-2010), from the Regione Liguria, Progetto LIMONTE (2009-2010), Ricerca Sanitaria Regionale (2010)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funded as Principal Investigator from the Fondazione Italiana Sclerosi Multipla (Progetto Speciale Cellule Staminali (2008-present), Fondazione CARIGE (2008-present)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health Unit (I.G., A.L., F.B., G.M., N.K.d.R., A.U.), and Center of Excellence for Biomedical Research (CEBR) (F.I., A.L., G.M., A.U.), University of Genoa, Italy; Ospedale Policlinico San Martino–IRCCS (A.L., G.M., A.U.), Genoa, Italy; and Rehabilitation Unit (C.S.), Centro di Recupero e Rieducazione Funzionale, M.L. Novarese, Moncrivello, Italy.
  1. Correspondence to Dr. Uccelli: auccelli{at}neurologia.unige.it
View Full Text

Article usage

Article usage: October 2017 to April 2022

AbstractFullPdfSource
Oct 2017174218Highwire
Nov 20172632948Highwire
Nov 2017375789pmc
Dec 201723217Highwire
Jan 201822719Highwire
Feb 201802913Highwire
Mar 201822311Highwire
Apr 201807510Highwire
Apr 2018142223pmc
May 20182883Highwire
Jun 201816713Highwire
Jun 201892125pmc
Jul 20180662Highwire
Aug 20181185Highwire
Aug 201881720pmc
Sep 20180288Highwire
Oct 20183335Highwire
Nov 20181515Highwire
Dec 20181866Highwire
Jan 20191658Highwire
Feb 20191564Highwire
Mar 20191297Highwire
Apr 2019288Highwire
May 201951610Highwire
Jun 2019296Highwire
Jul 201921111Highwire
Aug 201911111Highwire
Sep 2019293Highwire
Oct 201921210Highwire
Nov 2019197Highwire
Dec 20192165Highwire
Jan 20204913Highwire
Feb 20204158Highwire
Mar 202021614Highwire
Apr 20202105Highwire
May 20202124Highwire
Jun 20202106Highwire
Jul 20202095Highwire
Aug 2020036Highwire
Sep 2020193Highwire
Oct 20203212Highwire
Nov 202022010Highwire
Dec 20206122Highwire
Jan 20213810Highwire
Feb 2021489Highwire
Mar 2021042Highwire
Apr 20213812Highwire
May 20211114Highwire
Jun 20213187Highwire
Jul 202121510Highwire
Aug 20215116Highwire
Sep 20217612Highwire
Oct 202171621Highwire
Nov 202111716Highwire
Dec 202123116Highwire
Jan 20221266Highwire
Feb 2022153Highwire
Mar 202221612Highwire
Apr 2022095Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement